Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Amalgamated Bank grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,468 shares of the biopharmaceutical company’s stock after acquiring an additional 615 shares during the quarter. Amalgamated Bank’s holdings in Alnylam Pharmaceuticals were worth $3,087,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Bayforest Capital Ltd raised its stake in shares of Alnylam Pharmaceuticals by 14.6% during the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 39 shares in the last quarter. Fulton Bank N.A. raised its stake in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 46 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Alnylam Pharmaceuticals by 10.3% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 49 shares in the last quarter. Edmond DE Rothschild Holding S.A. raised its stake in shares of Alnylam Pharmaceuticals by 18.2% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 49 shares in the last quarter. Finally, Lindbrook Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 50 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,568,138.45. The trade was a 12.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last quarter. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. Needham & Company LLC lifted their target price on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Evercore ISI lifted their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 10th. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $478.67.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $434.07 on Tuesday. The stock has a market cap of $56.90 billion, a price-to-earnings ratio of -175.74 and a beta of 0.36. The firm’s 50-day moving average is $460.00 and its 200 day moving average is $372.32. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. The company had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s revenue was up 149.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.